Eurofins Technologies Launches a New Multiplex RT-PCR Assay for Combined SARS-CoV-2 Screening and Rapid Detection of the Omicron (B.1.1.529) Variant of Concern
3.12.2021 16:05:00 EET | Business Wire | Press release
Eurofins Technologies (Paris:ERF) announces the launch of the multiplex RT-PCR assay GSD NovaType Detect + Select K417N SARS-CoV-2. Within just one week since the first reports on the Omicron variant of concern, this kit has been developed as a quick response to identify its presence. The assay is designed for the simultaneous qualitative detection of SARS-CoV-2 genomic RNA and identification of the spike (S) mutation K417N in one reaction.
The results of this RT-PCR assay can be obtained within 1 hour, which makes it a fast and cost-effective solution to identifying the presence of the Omicron variant before samples are confirmed by whole genome sequencing.
Eurofins Technologies is constantly working to adapt its product offering to meet the challenges of the ongoing COVID-19 pandemic..
For more information, please visit Eurofins Technologies website.
About Eurofins Technologies – a fast growing provider of diagnostic technologies in the field of immunoassays and molecular detection methods
Building on the experience and scientific excellence of the Eurofins Group, Eurofins Technologies is a fast growing global provider of diagnostic technologies and industry-leading ELISA-based instruments in the field of bioanalytical testing for the food, feed, environmental, animal health, and clinical diagnostics industries.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With 55,000 staff across a network of 900 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211203005288/en/
Contact information
Rodrigo Berlie
ir@eurofins.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Eaton vahvistaa eurooppalaista tuotantoaan laajentamalla tuotantolaitostaan Itävallassa1.10.2026 10:00:00 EEST | Tiedote
Eaton juhlistaa Itävallassa sijaitsevan Schremsin tuotantolaitoksensa laajennusta 1. lokakuuta 2026. Laajennus vastaa sähköistymisen ja digitalisaation kasvattamaan kysyntään kaikkialla Euroopassa sekä lisää sähköisten suojaus- ja sähkönhallintaratkaisujen alueellista tuotantokapasiteettia. Alle kymmenessä kuukaudessa valmistunut laajennus yhdistää täysin automatisoidun tuotannon, edistyneen digitaalisen integraation ja tuotteiden end-to-end -jäljitettävyyden. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20261001549090/fi/ Eaton expanded manufacturing capacity in Europe for power management solutions in Schrems, Austria. ”Asiakkaat investoivat kaikkialla Euroopassa kriittiseen infrastruktuuriin, joka pitää yritykset toiminnassa, tukee talouskasvua ja vastaa kasvavaan sähkön kysyntään. Tämä laajennus kuvastaa jatkuvia investointejamme tuotantoon, teknologiaan ja osaavaan työvoimaan. Samalla se lisää niiden tuotteiden ja ra
Aegir Insights Launches Next-Generation Energy Intelligence Platform1.10.2026 10:00:00 EEST | Press release
Aegir Insights today announced the launch of its next-generation energy intelligence platform, combining commercial data, expert research and investment modeling in a single environment for investment decisions across onshore wind, offshore wind, solar, energy storage and data centers. The Aegir Platform links the intelligence that informs commercial decisions in renewables: Markets, companies, projects, auctions, supply chains and transactions. Together with analyst research and investment software, it gives the full context to assess where to invest, which assets and counterparties to consider, and what determines their viability. "Energy investment depends on understanding how projects, companies and markets fit together," said Scott Urquhart, CEO of Aegir Insights. "An asset's ownership, auction position, supply chain and route to market all shape its investment case. We connect that commercial context to Aegir's established investment modeling, laying the foundation for renewables
Advanced MRI Imaging Reveals Changes in Muscle Composition and Fat Infiltration During Obesity Treatment1.10.2026 09:55:00 EEST | Press release
As obesity treatment continues to evolve, understanding what happens to muscle during weight loss is becoming increasingly important. At the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD),AMRA Medical Chief Scientific Officer Dr. Jennifer Linge will present how advanced MRI-based analysis can provide a more detailed view of changes in muscle composition during obesity treatment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930545312/en/ Advanced MRI-based analysis can provide a more detailed view of changes in muscle composition during obesity treatment The presentation addresses an increasingly important question in obesity research: what happens to muscle as people lose weight?Understanding muscle composition changes is important because muscle health is about more than muscle size alone. Research using AMRA’s MRI-derived biomarkers has shown that muscle fat infiltration and muscle vo
Ares Strengthens Commitment to Plenitude Through €1 Billion Capital Contribution1.10.2026 09:30:00 EEST | Press release
Ares Management Corporation (NYSE: ARES), a leading global investment manager, announced today that Ares Alternative Credit funds (“Ares”) participated in a reorganization of the shareholding and governance structure of Plenitude through which Ares and Eni S.p.A (“Eni”) upsized their capital contribution by approximately €1.5 billion, of which over €1 billion is attributable to Ares, based on a pre-money equity valuation of Plenitude of €10.75 billion. Following completion of the transaction, Ares holds 26.24% of Plenitude’s share capital, with Eni holding 65.03% and Energy Infrastructure Partners (“EIP”) as an 8.73% shareholder. Ares first invested in Plenitude in 2025, acquiring a 20% stake in the business for approximately €2 billion. This transaction is geared towards strengthening Plenitude’s capital structure and introduces an enhanced governance framework that supports the company’s long-term growth ambitions. Ares and Eni will jointly control Plenitude, with Ares appointing thr
Orifarm Unveils 2031 Strategy to Accelerate Growth Across Europe, With Significant Expansion in Generics1.10.2026 09:10:00 EEST | Press release
With its five-year strategy, Fit to Scale, Orifarm sets out an ambitious path to scale across Europe, including a major expansion of its prescription medicines business from a Nordic footprint to a broader European platform. The strategy aims to double EBITDA to €300m and generate more than €3bn in revenue by 2031, marking the next step in Orifarm's journey as a diversified European pharmaceutical company bringing affordable medicines to more customers, patients and healthcare systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930257993/en/ Orifarm Headquarter, Odense Denmark “As European healthcare systems face rising demand, budget pressures, and supply challenges, Orifarm is uniquely positioned to improve access to affordable medicines and strengthen European supply. Our Fit to Scale strategy is about playing an even bigger role in meeting these needs and taking Orifarm to the next level,” says Mads Fink Eriksen,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom